- Headquarters
- New York, New York
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- hexemb.io
- Total Funding
- $7.5M
- Last Round
- $7.5M SeedFeb 2025
About
heXembio is a longevity therapeutics company developing the world's first rejuvenated hematopoietic stem cell therapy. Its platform restores the regenerative power of aged blood stem cells using a synthetic biology approach validated in peer-reviewed research published in Nature. The technology targets aging, immune health, and hematological conditions.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account